These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 22662786)

  • 1. Recurrent hepatotoxicity associated with etanercept and adalimumab but not with infliximab in a patient with rheumatoid arthritis.
    Titos Arcos JC; Hallal H; Robles M; Andrade RJ
    Rev Esp Enferm Dig; 2012 May; 104(5):282-4. PubMed ID: 22662786
    [No Abstract]   [Full Text] [Related]  

  • 2. Secondary syphilis following tumor necrosis factor-α inhibitor treatment for rheumatoid arthritis.
    Asahina A; Ishii N; Tohma S
    J Dermatol; 2012 Feb; 39(2):199-201. PubMed ID: 21463364
    [No Abstract]   [Full Text] [Related]  

  • 3. [TNF targetting therapy for rheumatoid arthritis].
    Takeuchi T
    Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1787-94. PubMed ID: 17037316
    [No Abstract]   [Full Text] [Related]  

  • 4. [Should we be afraid of the anti-TNFalpha drugs in 2008?].
    Gaudin P
    Rev Med Interne; 2008 Dec; 29(12):971-4. PubMed ID: 18571291
    [No Abstract]   [Full Text] [Related]  

  • 5. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which TNF inhibitor for rheumatoid arthritis?
    Med Lett Drugs Ther; 2010 May; 52(1338):38-9. PubMed ID: 20467356
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapeutic efficacy and the adverse effects of newly developed biological agents for rheumatoid arthritis].
    Kondo H
    Nihon Naika Gakkai Zasshi; 2004 Jan; 93(1):153-60. PubMed ID: 14968591
    [No Abstract]   [Full Text] [Related]  

  • 8. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients.
    Brocq O; Albert C; Roux C; Gerard D; Breuil V; Ziegler LE
    Joint Bone Spine; 2004 Nov; 71(6):601-3. PubMed ID: 15589452
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events.
    Mendes D; Alves C; Batel-Marques F
    J Clin Pharm Ther; 2014 Jun; 39(3):307-13. PubMed ID: 24635532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between adalimumab, etanercept, and infliximab in rheumatoid arthritis: comment on the article by Hetland et al.
    Francis S; Block MJ
    Arthritis Rheum; 2010 Sep; 62(9):2826; author reply 2826-8. PubMed ID: 20556822
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of treatment intensification with adalimumab, etanercept and infliximab in rheumatoid arthritis: a systematic review of cohort studies with focus on dose.
    Eng G; Stoltenberg MB; Szkudlarek M; Bouchelouche PN; Christensen R; Bliddal H; Marie Bartels E
    Semin Arthritis Rheum; 2013 Oct; 43(2):144-51. PubMed ID: 23838092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab efficacy in rheumatoid arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.
    Fleischmann R; Goldman JA; Leirisalo-Repo M; Zanetakis E; El-Kadi H; Kellner H; Bolce R; DeHoratius R; Wang J; Decktor D
    Curr Med Res Opin; 2014 Nov; 30(11):2139-49. PubMed ID: 25050591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA; Agudo M
    Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.
    Neovius M; Arkema EV; Olsson H; Eriksson JK; Kristensen LE; Simard JF; Askling J;
    Ann Rheum Dis; 2015 Feb; 74(2):354-60. PubMed ID: 24285495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to: 'Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register)' by Iannone et al.
    Neovius M; Askling J
    Ann Rheum Dis; 2014 Jun; 73(6):e32. PubMed ID: 24638970
    [No Abstract]   [Full Text] [Related]  

  • 17. Retention rates of adalimumab, etanercept and infliximab as first and second-line biotherapy in patients with rheumatoid arthritis in daily practice.
    Frazier-Mironer A; Dougados M; Mariette X; Cantagrel A; Deschamps V; Flipo RM; Logeart I; Schaeverbeke T; Sibilia J; Le Loët X; Combe B
    Joint Bone Spine; 2014 Jul; 81(4):352-9. PubMed ID: 24721422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-TNF therapy in rheumatoid arthritis].
    Yakeuchi T; Amano K
    Nihon Rinsho Meneki Gakkai Kaishi; 2004 Feb; 27(1):7-15. PubMed ID: 15045810
    [No Abstract]   [Full Text] [Related]  

  • 19. Recurrent allergic bronchopulmonary aspergillosis in a patient with rheumatoid arthritis treated with etanercept and tocilizumab.
    Honda H; Kida H; Yoshida M; Tomita T; Fujii M; Ihara S; Goya S; Tachibana I; Kawase I
    Mod Rheumatol; 2011 Dec; 21(6):660-4. PubMed ID: 21472474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of refractory tumor necrosis factor inhibitor-induced palmoplantar pustulosis: a report of 2 cases.
    Chu DH; Van Voorhees AS; Rosenbach M
    Arch Dermatol; 2011 Oct; 147(10):1228-30. PubMed ID: 22006150
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.